Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12449MR)

This product GTTS-WQ12449MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000878.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3560
UniProt ID P14784
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12449MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12734MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ15116MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ5241MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ3953MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ8673MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ3492MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ450MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ6195MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-870893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW